AZ Groeninge

Running trials

• Not yet recruiting

  Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT)

  NCT07782112· Phase 3· Source

• Not yet recruiting

  INPACT: Implementation of Nutritional Support and Physical Activity During Cancer Treatment

  NCT07929597· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  A Study of TAK-755 in Adults With Acute Ischemic Stroke

  NCT07392450· Phase 2· Source

• Recruiting

  LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer

  NCT06831955· Phase 2· Source

• Recruiting

  The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

  NCT07359599· Phase 4· Source

• Recruiting

  Effect of IMT in Patients After Acute Exacerbations of COPD

  NCT07213128· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Source

• Recruiting

  Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

  NCT06925984· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· Phase 3· Source

• Recruiting

  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

  NCT06719440· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Recruiting

  Improving the Use of Immunotherapy to Treat Liver Cancer

  NCT07623265· Source

• Recruiting

  The Prevalence and the Pathophysiological Role of Non-Helicobacter Pylori Helicobacter Spp. in Well-defined Gastric Diseases and (Pre-) Malignancies

  NCT07770126· Source

• Recruiting

  Salvage Stereotactic Body Radiotherapy of the Prostate Bed for Biochemical Recurrence After Radical Prostatectomy.

  NCT06523634· Source

• Recruiting

  Study on the Clinical Efficacy of Teclistamab and Talquetamab

  NCT06477783· Source

• Enrolling by invitation

  Snapshot Study on Patients With Heart Failure

  NCT06469814· Source

• Recruiting

  Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

  NCT06691425· Source

• Recruiting

  The RECLAIM Study.

  NCT06450444· Source

• Recruiting

  Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  NCT06276491· Phase 1· Source

• Recruiting

  Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

  NCT06282588· Phase 2/3· Source

• Recruiting

  Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

  NCT06896890· Phase 1/2· Source

• Recruiting

  A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

  NCT05862285· Phase 3· Source

• Active, not recruiting

  EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

  NCT05029414· Source

• Recruiting

  Belgian Registry on Coronary Function Testing

  NCT06089031· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

  NCT04675333· Phase 2· Source

• Active, not recruiting

  Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

  NCT04675294· Phase 2· Source

• Active, not recruiting

  Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

  NCT04579380· Phase 2· Source

• Active, not recruiting

  Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

  NCT04509700· Phase 2· Source

• Active, not recruiting

  PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases

  NCT03569241· Phase 2· Source

• Active, not recruiting

  A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

  NCT03473743· Phase 1/2· Source

• Active, not recruiting

  A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT03431350· Phase 2· Source

• Active, not recruiting

  ASPIRIN Trial Belgium

  NCT03464305· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Prostate cancer3 recruiting
• Liver and biliary tract cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Stroke2 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Gastric and esophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

  NCT05992142· Phase 4· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy

  NCT04813627· Source

• Completed

  A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

  NCT04836559· Phase 2· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Source

• Completed

  CERENOVUS Neurothrombectomy Devices Registry

  NCT03685578· Source

• Completed

  DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

  NCT03523585· Phase 3· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006· Phase 3· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Source

• Completed

  R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

  NCT01865110· Phase 3· Source